Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine

Estela Giménez; Eliseo Albert; Joao Zulaica; Ignacio Torres; Luciana Rusu; Alicia Rodríguez Moreno; Javier S Burgos; Salvador Peiró; Dolores Salas; Hermelinda Vanaclocha; Ramón Limón; María Jesús Alcaraz; José Sánchez-Payá; Javier Díez-Domingo; Iñaki Comas; Fernando Gonzáles-Candelas; Ron Geller; David Navarro; Valencian Vaccine Research Program (ProVaVac) Study Group

doi:10.1093/cid/ciac223

Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine

Clin Infect Dis. 2022 Aug 24;75(1):e865-e868. doi: 10.1093/cid/ciac223.

Authors

Estela Giménez¹, Eliseo Albert¹, Joao Zulaica², Ignacio Torres¹, Luciana Rusu², Alicia Rodríguez Moreno², Javier S Burgos³, Salvador Peiró⁴, Dolores Salas^{4

5}, Hermelinda Vanaclocha⁵, Ramón Limón⁶, María Jesús Alcaraz¹, José Sánchez-Payá^{7

8}, Javier Díez-Domingo⁴, Iñaki Comas^{9

10}, Fernando Gonzáles-Candelas^{2

10}, Ron Geller², David Navarro^{1

11}; Valencian Vaccine Research Program (ProVaVac) Study Group

Collaborators

Valencian Vaccine Research Program (ProVaVac) Study Group:
J S Burgos, R Meneu de Guillerna, Luna H Vanaclocha, D J Burks, A Cervantes, I Comas, J Díez-Domingo, S Peiro, F González-Candelas, Albiach C Ferrer, I Hernández-Aguado, Ramírez N Oliver, J Sánchez-Payá, Torres M Vento, Latorre E Zapater, D Navarro

Affiliations

¹ Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
² Institute for Integrative Systems Biology, Universitat de Valencia-Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.
³ General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain.
⁴ Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain.
⁵ General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
⁶ General Directorate of Healthcare, Department of Health, Valencian Government, Valencia, Spain.
⁷ Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain.
⁸ Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain.
⁹ Biomedicine Institute of Valencia, Spanish Research Council (CSIC), Valencia, Spain.
¹⁰ Centro Nacional de Investigación Biomédica en Red (CIBER) in Epidemiology and Public Health, SpainJoint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain.
¹¹ Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.

Abstract

A third Comirnaty vaccine dose increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain antibody levels (median, 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (me 22-fold), Delta, (median, 43-fold), and Omicron (median, 8-fold) variants, but had less impact on S-reactive T-cell immunity in nursing home residents.

Keywords: Comirnaty COVID-19 vaccine third dose; SARS-CoV-2-S T cells; SARS-CoV-2-S antibodies; neutralizing antibodies; nursing home residents.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adaptive Immunity
Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Neutralization Tests
Nursing Homes
SARS-CoV-2
Viral Vaccines*

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
Viral Vaccines